S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Stellar Biotechnologies Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
+0.13 (+2.61 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $5.11
50-Day Range
MA: $59,624.23
52-Week Range
Now: $5.11
Volume279,362 shs
Average Volume2.95 million shs
Market Capitalization$27.24 million
P/E RatioN/A
Dividend YieldN/A
Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.
Stellar Biotechnologies logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SBOT
Year FoundedN/A



Sales & Book Value

Annual Sales$210,000.00
Book Value$2.12 per share


Net Income$-5,030,000.00
Net Margins-1,782.64%


Market Cap$27.24 million
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.63 out of 5 stars

Medical Sector

1316th out of 1,968 stocks

Pharmaceutical Preparations Industry

589th out of 771 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Receive SBOT News and Ratings via Email

Sign-up to receive the latest news and ratings for SBOT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Stellar Biotechnologies (NASDAQ:SBOT) Frequently Asked Questions

What stocks does MarketBeat like better than Stellar Biotechnologies?

Wall Street analysts have given Stellar Biotechnologies a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Stellar Biotechnologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Stellar Biotechnologies' earnings last quarter?

Stellar Biotechnologies Inc (NASDAQ:SBOT) released its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.05. The biotechnology company had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.11 million. Stellar Biotechnologies had a negative net margin of 1,782.64% and a negative trailing twelve-month return on equity of 51.12%.
View Stellar Biotechnologies' earnings history

When did Stellar Biotechnologies' stock split? How did Stellar Biotechnologies' stock split work?

Stellar Biotechnologies's stock reverse split on the morning of Monday, May 7th 2018. The 1-7 reverse split was announced on Friday, April 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 4th 2018. An investor that had 100 shares of Stellar Biotechnologies stock prior to the reverse split would have 14 shares after the split.

Who are Stellar Biotechnologies' key executives?

Stellar Biotechnologies' management team includes the following people:
  • Mr. Frank R. Oakes, Chairman, Pres & CEO (Age 69)
  • Ms. Kathi Niffenegger CPA, CFO & Corp. Sec. (Age 62)
  • Mr. Gary Koppenjan, Sr. Director of Investor Relations & Communications
  • Brando Lincicum, Exec. Director of Aquaculture and Facility Operations

Who are some of Stellar Biotechnologies' key competitors?

What other stocks do shareholders of Stellar Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stellar Biotechnologies investors own include Heat Biologics (HTBX), XOMA (XOMA), (NXE.V) (NXE), Anavex Life Sciences (AVXL), EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), 426673 (STO), Abraxas Petroleum (AXAS) and Carrizo Oil & Gas (CRZO).

What is Stellar Biotechnologies' stock symbol?

Stellar Biotechnologies trades on the NASDAQ under the ticker symbol "SBOT."

What is Stellar Biotechnologies' stock price today?

One share of SBOT stock can currently be purchased for approximately $5.11.

How much money does Stellar Biotechnologies make?

Stellar Biotechnologies has a market capitalization of $27.24 million and generates $210,000.00 in revenue each year. The biotechnology company earns $-5,030,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

How many employees does Stellar Biotechnologies have?

Stellar Biotechnologies employs 25 workers across the globe.

What is Stellar Biotechnologies' official website?

The official website for Stellar Biotechnologies is www.stellarbiotechnologies.com.

Where are Stellar Biotechnologies' headquarters?

Stellar Biotechnologies is headquartered at 332 EAST SCOTT STREET, PORT HUENEME CA, 93041.

How can I contact Stellar Biotechnologies?

Stellar Biotechnologies' mailing address is 332 EAST SCOTT STREET, PORT HUENEME CA, 93041. The biotechnology company can be reached via phone at 805-488-2800 or via email at [email protected]

This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.